Svaton M.,Klinika Pneumologie a Ftizeologie |
Kulda V.,Ustav Lekarske Chemie a Biochemie |
Mukensnabl P.,Sikluv Ustav Patologie |
Topolcan O.,Oddeleni Nuklearni Mediciny Imunoanalyticka Laborator |
And 6 more authors.
Studia Pneumologica et Phthiseologica | Year: 2017
Introduction: Adjuvant chemotherapy has become an integral part of treatment of radically operated patients with lung cancer stages 2, 3 and IB larger than 4 cm. For smaller tumors (stages IB and 1A), the benefits of this treatment have not been demonstrated for the overall patient population. However, it is known that the risk of disease recurrence following surgical removal of the tumor is not negligible. The aims were to assess the relationship between expression of selected protein-coding genes and microRNAs and disease-free interval (DFI) and overall survival (OS) in patients with early-stage lung adenocarcinoma and to try to find a possible marker of risk of disease recurrence and thus identify the patient population that might benefit from adjuvant chemotherapy. Patients and Methods: The study included 42 patients (31 males and 11 females; all but 4 patients were smokers or ex-smokers) with radically operated stage 1A and IB lung adenocarcinoma not receiving adjuvant chemotherapy. Expression of selected mRNAs and miRNAs was measured by quantitative RT-PCR in tumor tissues obtained by macrodissection from formalin-fixed paraffin-embedded (FFPE) tissue biopsies. The relationships between gene expression levels of selected mRNAs and miRNAs and DFI and OS was analyzed. Results: In the entire set of mRNAs and microRNAs of interest, no statistically significant relationship was found between their expression and DFI or OS. In the subgroup of smokers or ex-smokers only, a significant relationship was demonstrated between the mRNA level of BRCA1 and OS. Conclusion: Using routinely prepared FFPE tumor samples, a relationship between shorter OS and the level of BRCA1 was demonstrated in the subgroup of smokers or ex-smokers. Given the small sample size, however, the results need to be confirmed by further studies.
Polivka J.,Neurologicka Klinika |
Repik T.,Neurologicka Klinika |
Holubec L.,Biomedicinske Centrum
Ceska a Slovenska Neurologie a Neurochirurgie | Year: 2017
Recently updated classification of the central nervous system (CNS) tumours prepared by the World Health Organization (WHO) in 2016 uses, in addition to the histopathological criteria, also molecular genetic characteristics (biomarkers) of tumour cells and introduces the so-called integrated diagnostics concept for the first time. Molecular genetic biomarkers often have a major impact on the patients' prognosis and/or selection of an appropriate therapy in a variety of tumour entities. This update represents a significant progress compared to the 2007 classification of CNS tumours. The more precise classification of tumours using well-known and widely accepted molecular genetic biomarkers, will also facilitate further research in anticancer therapeutics and consistent inclusion of patients into clinical trials. The presence of a tumour group called "not otherwise specified" (NOS) is the major drawback of this novel approach. Tumours currently classified as the NOS entities are likely to be more accurately characterized with an ongoing neurooncological research in molecular genetics. The operational and technical barriers of molecular genetic analyses will be also overcome and this will further enable significant reduction of the NOS tumour entities. It is assumed that the new classification will facilitate clinical, experimental as well as epidemiological studies and thereby will improve the life of patients with brain tumours. This review presents the key findings from the new classification of the CNS tumours together with their clinical sequelae.
Holubec L.,Biomedicinske centrum |
Fiala O.,Biomedicinske centrum |
Matejka V.M.,Biomedicinske centrum |
Liska V.,Biomedicinske centrum |
And 2 more authors.
Onkologie (Czech Republic) | Year: 2014
Colorectal cancer has the highest incidence rate in the Czech Republic and occupies one of the leading positions in incidence worldwide. Only patients with resectable distant metastases have hope for a cure. Prolongation of survival and improvement in the quality of life thus remain the main goal of cancer treatment. The possibilities of classic chemotherapy appear to be currently exhausted. Further prolongation of survival of patients with metastatic colorectal cancer (mCRC) has been provided by targeted biological therapy. It is crucial to find suitable predictive biomarkers that will allow identification of a target population of patients. The review article analyses the RAS mutation status with respect to the possible sequence of targeted biological therapy in patients with mCRC with regard to the new data presented at ASCO 2014.
Holubec L.,Onkologicka a radioterapeuticka klinika |
Liska V.,Biomedicinske centrum |
Finek J.,Onkologicka a radioterapeuticka klinika
Klinicka Onkologie | Year: 2015
Background: The efficacy of anticancer therapy is regularly evaluated using the following indicators - objective response rate, progression free survival and overall survival. The change in the tumor burden extent is assessed by the cumulative change in the size of target tumor lesions using imaging methods where WHO and RECIST criteria are most frequently used. The main problem of these criteria is that they use different definitions of response rate evaluation. Generally, existing results of these evaluations do not confirm a direct correlation between the objective response rate and survival (progression free survival or overall survival). Another problem of these methods is that the results of the assessment do not correlate with the biological activity of tumor growth, since it is a static evaluation of clinical status. /Mm: This review article provides an overview of results related to new possibilities for evaluating the efficacy of anticancer therapy using the concept of depth of response and the concept of early tumor shrinkage in patients with metastatic colorectal cancer. Conclusion: The results of numerous post-hoc and exploratory analyses of clinical studies consistently suggest that early tumor shrinkage and depth of response are important variables in assessing the efficacy of systemic anticancer treatment.